PureWay-C (Vitamin C)

PureWay-C is a patented form of vitamin C (ascorbic acid) complexed with lipid metabolites and citrus bioflavonoids, designed to enhance cellular uptake and retention compared to standard ascorbic acid. Its primary mechanism involves lipid-facilitated transport that improves intracellular delivery of ascorbate, supporting immune function and antioxidant defense.

Origin & History

PureWay-C is a patented branded form of vitamin C that combines ascorbic acid with lipid metabolites from plant sources (such as triglycerides) and citrus bioflavonoids. It is produced in the United States by manufacturers like One Innovation and NutriScience using a proprietary process that creates a liposomal or lipid-complexed structure, confirmed by transmission electron microscopy.

Historical & Cultural Context

No historical or traditional medicine context exists for PureWay-C, as it is a modern patented formulation with no links to traditional systems like Ayurveda, TCM, or ethnobotany. While vitamin C itself has historical significance in preventing scurvy, PureWay-C's lipid-complex technology is proprietary and recent.

Health Benefits

• Enhanced vitamin C absorption with 233% higher cellular retention after 24 hours compared to regular ascorbic acid (based on one human bioavailability study, n=12)
• Superior free radical scavenging activity achieving nearly 100% reduction of DPPH radicals at 20 μg/ml in vitro (human antioxidant outcomes inferred from pharmacokinetics)
• Rapid serum peaks within 1-6 hours post-ingestion with prolonged tissue retention (limited to single crossover study)
• Protection from stomach acid degradation and oxidation due to lipid complex formulation (mechanism-based benefit, not clinically tested)
• Improved intracellular vitamin C levels through lipid-mediated transport bypassing saturable transporters (based on epithelial cell studies)

How It Works

PureWay-C combines ascorbic acid with fatty acid metabolites (including fatty alcohols and esters) that facilitate absorption via lipid-mediated transport pathways, potentially bypassing the saturable sodium-dependent vitamin C transporters (SVCT1 and SVCT2) that limit standard ascorbic acid uptake. Once intracellular, ascorbate acts as a cofactor for prolyl and lysyl hydroxylases involved in collagen synthesis and serves as a direct electron donor to neutralize reactive oxygen species including superoxide, hydroxyl radicals, and singlet oxygen. The bioflavonoid components may also inhibit ascorbate oxidation in the gut, preserving bioavailable ascorbate concentration before systemic absorption.

Scientific Research

Clinical evidence for PureWay-C is limited to one human bioavailability study from 2007 (PMID: 17901843) involving 12 healthy volunteers in a randomized crossover design, showing superior absorption compared to other vitamin C forms. No large-scale RCTs, meta-analyses, or additional PubMed-listed human trials specific to PureWay-C were identified, with claims relying primarily on this single study and in vitro data.

Clinical Summary

A small human bioavailability study (n=12) found that PureWay-C achieved 233% higher cellular retention of vitamin C at 24 hours compared to regular ascorbic acid, though the limited sample size requires cautious interpretation. An in vitro study demonstrated near-complete (approximately 100%) reduction of DPPH free radicals at a concentration of 20 μg/ml, indicating potent antioxidant capacity under laboratory conditions. Comparative studies against other vitamin C forms such as Ester-C and calcium ascorbate have suggested faster absorption kinetics for PureWay-C, but most trials are industry-sponsored and involve small cohorts. Larger, independent, randomized controlled trials are needed to confirm clinical significance for immune endpoints such as infection duration or severity.

Nutritional Profile

PureWay-C is a patented form of vitamin C (ascorbic acid) complexed with lipid metabolites (fatty acid esters and fatty alcohols derived from vegetable sources), designed to enhance bioavailability and cellular retention. Primary active compound: ascorbic acid, typically delivered at supplemental doses of 500–1000 mg per serving depending on formulation. The lipid metabolite complex constitutes a minor but functionally critical fraction of the total composition, facilitating enhanced membrane transport and intracellular uptake. No meaningful macronutrient contribution (negligible protein, fat, or carbohydrate at typical doses). Micronutrient profile is dominated entirely by vitamin C (ascorbic acid), contributing to the RDA of 65–90 mg/day for adults, though supplemental doses far exceed this. Bioavailability data: one human pharmacokinetic study (n=12) demonstrated 233% higher cellular retention at 24 hours post-ingestion compared to standard ascorbic acid; serum concentration peaks occur within 1–6 hours post-ingestion. In vitro antioxidant capacity: near 100% DPPH radical scavenging at 20 μg/ml concentration. No fiber, no significant mineral content, no protein. The lipid carrier component does not contribute caloric density at supplemental serving sizes in any nutritionally meaningful way.

Preparation & Dosage

The clinically studied dosage used 1 gram of PureWay-C powder, showing peak absorption superior to equivalent doses of regular ascorbic acid or calcium ascorbate. Typical formulations contain 65-90% vitamin C potency with added lipid metabolites and citrus bioflavonoids, with general supplement use ranging from 500-1000 mg daily. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Citrus bioflavonoids, Quercetin, Zinc, Vitamin E, Alpha-lipoic acid

Safety & Interactions

PureWay-C shares the general safety profile of vitamin C; doses up to 2,000 mg/day are considered the tolerable upper intake level for adults by the Institute of Medicine, with higher doses risking gastrointestinal distress, diarrhea, and osmotic effects. High-dose vitamin C can interfere with certain lab tests including serum glucose and creatinine assays, and may enhance iron absorption, which is a concern for individuals with hemochromatosis. Vitamin C at pharmacological doses may reduce the efficacy of certain chemotherapy agents (e.g., bortezomib) and may interact with anticoagulants like warfarin by potentially altering clotting factor stability. PureWay-C is generally considered safe during pregnancy at recommended dietary allowance levels (85 mg/day for pregnant women), but high-dose supplementation during pregnancy lacks sufficient safety data and should be avoided without medical supervision.